Allergan receives FDA ’s RTF letter for Vraylar sNDA to treat schizophrenia
Allergan ’s supplemental new drug application (sNDA) for Vraylar (cariprazine) to treat negative symptoms associated with schizophrenia in adult patients has received a Refusal to File (RTF) letter from the US Food and Drug Administration (FDA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Allergy | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals | Schizophrenia